CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 20 enrolled
Drug / intervention
Organoid culturegenetic
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04342286
NCT04342286N/ACompleted

To Establish a Reproducible Organoid Culture Model With Human Kidney Cancer

Chinese University of Hong Kong·observational·Posted Apr 13, 2020·Updated Dec 16, 2021

In Brief

An observational study evaluating Organoid culture for Kidney Cancer. Completed, enrolled 20 participants across 1 site.

Detailed Summary

Kidney cancer is one of the ten most common malignancies, and the incidence is increasing in recent year. From Hong Kong Cancer Registry, there was about 670 new cases diagnosed in 2016, and had been increased by 46% compared to 2007.Within the broad classification of kidney cancers, renal cell carcinoma (RCC) accounts for approximately 85% of all cases and greater than 90% of all renal malignancies. Despite the improved understanding and also diagnosis for kidney cancer, still about one fourth of patients will presented at metastatic stage or developed recurrence after initial treatment and required further systemic therapy. Facing the wide range of available options for systemic therapy, the current challenge is how to select the most effective treatment. Unfortunately, there is no good biomarkers available to aid treatment selection. Currently, there are some approaches to try to test the response of kidney cancer to different chemotherapeutic agents. Previous studies showed that 3D organoid culture model can improve our ability to model tumor behavior. Organoid culture technology may provide opportunities for new drug development and drug screening. In this study, investigators aim to establish a reliable and effective method to cultivate kidney cancer cells, then will provide researchers for further information on personalized and targeted therapy on kidney cancer for local Hong Kong patients.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsKidney Cancer
CountriesHong Kong
Collaborators--

Timeline

N/ACompletedFinished
202120222023202420252026
First PostedApr 13, 2020
Enrollment StartMay 1, 2020
Primary CompletionFeb 22, 2021
TodayJul 1, 2026
Enrollment to primary: 10 monthsPosted 6.2 years ago

Interventions

Organoid culturegenetic

Organoid culture